Download PDF
Semin Respir Crit Care Med 2000; Volume 21(Number 05): 385-392
DOI: 10.1055/s-2000-9402
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Screening for Lung Cancer in High-Risk Groups: Current Status of Low-Dose Spiral CT Scanning and Sputum Markers

James R. Jett
  • Pulmonary Medicine and Medical Oncology, Mayo Clinic, Rochester, Minnesota
Further Information

Publication History

Publication Date:
31 December 2000 (online)

    Permissions and Reprints

ABSTRACT

Lung cancer is the number one cause of death from cancer in the United States. Currently, there is no official recommendation to screen for lung cancer even in high-risk populations. Accordingly, we wait for patients to present with symptoms. Only 15-20% of patients are stage I lung cancer at diagnosis. Past screening trials with chest roentgenogram and sputum cytology did not show a reduction of lung cancer mortality in the screened population. Since the completion of those trials in the early 1980s we have learned that the chest X ray is not sensitive at detecting lesions <2 cm in size, and patients with chronic obstructive pulmonary disease (COPD) have a 4- to 6-fold increased risk of lung cancer independent of their smoking history. Recent trials with spiral computed tomography (CT) scan screening have detected 80-85% of lung cancers while they are stage I. The problems related to spiral CT screening are the cost and the frequent detection of benign lesions. Algorithms are being developed to try and prevent unnecessary biopsies and/or surgery. Sputum cytology is currently the only clinically approved sputum test for detecting lung cancer. However, in patients with moderate dysplasia of cytology, the LIFE autofluorescence bronchoscopy system may yield an increased sensitivity of detecting precancerous or cancerous lesions. More studies are needed before the LIFE system can be adopted as a standard clinical tool. Currently, investigators are evaluating the sputum for early lung cancer detection markers. The marker that is the most developed is the monoclonal antibody to the heterogeneous nuclear ribonucleoprotein A2/B1 on the sputum epithelial cell surface. Encouraging preliminary results have been reported and trials are ongoing. The future looks bright for the field of lung cancer screening.

KEYWORD

Lung cancer - low-dose spiral CT - sputum markers - COPD

REFERENCES

  • 1 Landis S H, Murray T, Bolden S, Wingo P A. Cancer Statistics, 1999.  CA . 1999;  49 8-31
    CrossrefPubMedGoogle Scholar
  • 2 Fontana R S, Sanderson D R, Taylor W F. Early lung cancer detection: Results of the initial (prevalence) radiologic and cytologic screening in the Mayo Clinic Study.  Am Rev Resp Dis . 1984;  130 561-565
    PubMedGoogle Scholar
  • 3 Thompson S, Bucknall C, Pearson M G. Presenting symptoms and signs of lung cancer-Significance and relation to tumor type.  Am J Resp Crit Care Med . 1999;  159(part 2 of 2) A61
    PubMedGoogle Scholar
  • 4 Janssen-Heijnen M LG, Gatta G, Forman D. Variation in survival in patients with lung cancer in Europe, 1985-1989.  Eur J Cancer . 1998;  34 2191-2196
    CrossrefPubMedGoogle Scholar
  • 5 Berlin N I, Buncher C R, Fontana R S. The National Cancer Institute Cooperative Early Lung Cancer Detection Program.  Am Rev Resp Dis . 1984;  130 545-549
    PubMedGoogle Scholar
  • 6 Frost J K, Ball W C, Levin M. Early lung cancer detection: Results of the initial prevalence radiologic and cytologic screening in the Johns Hopkins Study.  Am Rev Resp Dis . 1984;  130 549-554
    PubMedGoogle Scholar
  • 7 Flehinger B J, Melamed M R, Zaman M B. Early lung cancer detection: Results of the initial (prevalence) radiologic and cytologic screening in the Memorial Sloan-Kettering Study.  Am Rev Resp Dis . 1984;  130 555-560
    PubMedGoogle Scholar
  • 8 Early lung cancer detection: Summary and conclusions. Am Rev Resp Dis .  1984;  130 565-570
    PubMedGoogle Scholar
  • 9 Fontana R S, Sanderson D R, Woolner L B. Lung cancer screening: The Mayo Program.  J Occup Med . 1986;  28 746-750
    PubMedGoogle Scholar
  • 10 Melamed M R, Flehinger B J, Zaman M B. Screening for early lung cancer.  Chest . 1984;  86 44-53
    CrossrefPubMedGoogle Scholar
  • 11 Tockman M S. Survival and mortality from lung cancer in a screened population.  Chest . 89(suppl 0) 324S-325S
    PubMedGoogle Scholar
  • 12 Risch H A, Howe G R, Jain M. Are female smokers at higher risk for lung cancer than male smokers?.  Am J Epidemiol . 1993;  138 281-293
    CrossrefPubMedGoogle Scholar
  • 13 Zang E A, Wynder E L. Differences in lung cancer risk between men and women: Examination of the evidence.  J Natl Cancer Inst . 1996;  88 183-192
    CrossrefPubMedGoogle Scholar
  • 14 Prescott E, Bjerg A M, Andersen P K. Gender difference in smoking effects on lung function and risk of hospitalization for COPD: Results from a Danish longitudinal population study.  Eur Respir J . 1997;  10 822-827
    PubMedGoogle Scholar
  • 15 Mollerup S, Ryberg D, Hewer A. Sex difference in lung CYP1A1 expression and DNA adduct levels among lung cancer patients.  Cancer Res . 1999;  59 3317-3320
    PubMedGoogle Scholar
  • 16 Skillrud D M, Offord K P, Miller R D. Higher risk of lung cancer in chronic obstructive pulmonary disease.  Ann Int Med . 1986;  105 503-507
    PubMedGoogle Scholar
  • 17 Tockman M S, Anthonisen N R, Wright E. Airway obstruction and the risk of lung cancer.  Ann Int Med . 1987;  106 512-518
    PubMedGoogle Scholar
  • 18 Kuller L H, Ockene J, Meilahn E. Relation of forced expiratory volume in one second (FEV1) to lung cancer mortality in the multiple risk factor intervention trial (MRFIT).  Am J Epidemiol . 1990;  132 265-274
    PubMedGoogle Scholar
  • 19 Anthonisen N R, Connett J E, Kiley J P. Effects of smoking intervention and the use of inhaled anticholinergic bronchodilator on the rate of decline in FEV1: Lung Health Study.  JAMA . 1994;  272 1497-1505
    CrossrefPubMedGoogle Scholar
  • 20 Pigula F A, Keenan R J, Ferson P F, Landreneau R J. Unspuspected lung cancer found in work-up for lung reduction operation.  Ann Thorac Surg . 1996;  61 174-176
    CrossrefPubMedGoogle Scholar
  • 21 McKenna Jr R J, Fischel R J, Brenner M, Gelb A F. Combined operations for lung volume reduction surgery and lung cancer.  Chest . 1996;  110 885-888
    PubMedGoogle Scholar
  • 22 Clark-Ojo T, Martinez F, Paine III R. Lung volume reduction surgery alters management of pulmonary nodules in patients with severe COPD.  Chest . 1997;  112 494-1500
    PubMedGoogle Scholar
  • 23 Rozenshtein A, White C S, Austin J HM. Incidental lung carcinoma detected at CT in patients selected for lung volume reduction surgery to treat severe pulmonary emphysema.  Radiology . 1998;  207 487-490
    PubMedGoogle Scholar
  • 24 Muhm J R, Miller W E, Fontana R S. Lung cancer detected during a screening program using four-month chest radiographs.  Radiology . 1983;  148 609-615
    PubMedGoogle Scholar
  • 25 Austin J HM, Romney B M, Goldsmith L S. Missed bronchogenic carcinoma: Radiologic findings in 270 patients with a potentially resectable lesion evident in retrospect.  Radiology . 1992;  182 115-122
    PubMedGoogle Scholar
  • 26 Quekel G BA, Kessels A GH, Goei R, van Engelshoven J MA. Miss rate of lung cancer on the chest radiograph in clinical practice.  Chest . 1999;  115 720-724
    CrossrefPubMedGoogle Scholar
  • 27 Mountain C F. Revisions in the international system for lung cancer.  Chest . 1997;  111 1710-1717
    CrossrefPubMedGoogle Scholar
  • 28 Kaneko M, Eguchi K, Ohmatsu H. Peripheral lung cancer: Screening and detection with low-dose spiral CT versus radiography.  Radiology . 1996;  201 698-802
    PubMedGoogle Scholar
  • 29 Sone S, Takashima S, Li F. Mass screening for lung cancer with mobile spiral computed tomography scanner.  Lancet. 1998;  351 1242-1245
    CrossrefPubMedGoogle Scholar
  • 30 Ohmatsu H, Kakinuma R, Nishiwaki M. Lung cancer screening with low-dose spiral CT.  Proc Am Soc Clin Oncol . 1999;  18 463a
    PubMedGoogle Scholar
  • 31 Henschke C I, McCauley D I, Yankelevitz D F. Early lung cancer action project: Overall design and findings from baseline screening.  Lancet . 1999;  354 99-105
    CrossrefPubMedGoogle Scholar
  • 32 Kennedy T C, Proudfoot S P, Franklin W. Cytopathological analysis of sputum in patients with airflow obstruction and significant smoking histories.  Cancer Res . 1996;  56 4673-4678
    PubMedGoogle Scholar
  • 33 Lam S, Kennedy T, Unger M. Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy.  Chest . 1998;  113 696-702
    PubMedGoogle Scholar
  • 34 Kurie J M, Lee J S, Morice R C. Auto-fluorescence bronchoscopy in the detection of squamous metaplasia and dysplasia in current and former smokers.  J Natl Cancer Inst . 1998;  90 991-995
    CrossrefPubMedGoogle Scholar
  • 35 Testa R A, Siegfried J M, Liu Z. Cytogenetic analysis of 63 non-small cell lung carcinomas: Recurrent chromosomal alteration amid frequent and widespread genomic upheaval.  Genes Chromosomes Cancer . 1994;  11 178-194
    PubMedGoogle Scholar
  • 36 Mao L, Lee J S, Kurie J M. Clonal genetic alterations in the lungs of current and former smokers.  J Natl Cancer Inst . 1997;  89 857-862
    CrossrefPubMedGoogle Scholar
  • 37 Wistuba I I, Lam S, Behrens C. Molecular damage in bronchial epithelium of current and former smokers.  J Natl Cancer Inst . 1997;  89 1366-1373
    CrossrefPubMedGoogle Scholar
  • 38 Miozzo M, Sozzi G, Mussok M. Microsatellite alterations in bronchial sputum specimens of lung cancer patients.  Cancer Res . 1996;  56 2285-2288
    PubMedGoogle Scholar
  • 39 Kashiwabara K, Oyama T, Sano T. Correlation between methylation status of the p16/CDKN2 gene and the expression of p16 and Rb proteins in primary non-small cell lung cancers.  Int J Cancer . 1998;  79 215-220
    CrossrefPubMedGoogle Scholar
  • 40 Belinsky S A, Nikula K J, Palmisano W A. Aberrant methylation of p16 is an early event in lung cancer and a potential biomarker for early diagnosis.  Proc Natl Acad Sci . 1998;  95 11891-11896
    CrossrefPubMedGoogle Scholar
  • 41 Tockman M S, Gupta P K, Myers J D. Sensitive and specific monoclonal recognition of human lung cancer antigen on preserved sputum cells: A new approach to early lung cancer detection.  J Clin Oncol . 1988;  6 1685-1693
    PubMedGoogle Scholar
  • 42 Tockman M S, Mulshine J L, Piantadosi S. Prospective detection of preclinical lung cancer: Results from two studies of heterogeneous nuclear ribo- nucleoprotein A2/B1 over-expression.  Clinical Cancer Research . 1997;  3 2237-2246
    PubMedGoogle Scholar
      >